Treatment of patients resistant to anthracycline therapy

Anti-Cancer Drugs

Volumn 7, Issue SUPPL. 2, 1996, Pages 13-16

  Ravdin, P M ^a  

^a UNIVERSITY OF TEXAS HEALTH SCIENCE CENTER AT SAN ANTONIO   (United States)

Author keywords

anthracenediones; anthracyclines; docetaxel (Taxotere ); metastatic breast cancer

Indexed keywords

ANTHRACYCLINE DERIVATIVE; ANTHRAQUINONE DERIVATIVE; DIPHENHYDRAMINE; DOCETAXEL; METHYLPREDNISOLONE;

BREAST CANCER; CLINICAL TRIAL; CONFERENCE PAPER; FEMALE; HUMAN; INTRAVENOUS DRUG ADMINISTRATION; MAJOR CLINICAL STUDY; METASTASIS; MULTICENTER STUDY; NEUTROPENIA; ORAL DRUG ADMINISTRATION; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL;

EID: 0029792044     PISSN: 09594973     EISSN: None     Source Type: Journal    
DOI: 10.1097/00001813-199608002-00004     Document Type: Conference Paper

References (12)

1. Wingo PA, Tong T, Bolden S. Cancer statistics, 1995. CA 1995; 45: 8-30.
2. A'Hern RP, Smith IE, Ebbs SR. Chemotherapy and survival in advanced breast cancer: the inclusion of doxorubicin in Cooper type regimens. Br J Cancer 1993; 67: 801-805.
3. Henderson IC. Chemotherapy for metastatic disease. In: Harris JR, Hellman S, Henderson IC, et al., eds. Breast diseases (2nd edition). Philadelphia, PA: Lippincott; 1991: 604-665.
4. Henderson IC, Allegra JC, Woodcock T, et al. Randomized trial comparing mitoxantrone with doxorubicin in previously treated patients with metastatic breast cancer. J Clin Oncol 1989; 7: 560-571.
5. Valero V, Holmes FA, Walters RS, et al. Phase II trial of docetaxel: a new, highly effective antineoplastic agent in the management of patients with anthracycline-resistant metastatic breast cancer. J Clin Oncol 1995; 13: 2886-2894.
6. Ravdin PM, Burris HA, Cook G, et al. Phase II trial of docetaxel in advanced anthracycline-resistant or anthracenedione-resistant breast cancer. J Clin Oncol 1995; 13: 2879-2885.
7. Guastalla JP, Bonneterre J, Fumoleau P, et al. A phase II trial of docetaxel in patients with anthracycline resistant metastatic breast cancer [abstract], 8th European Conference on Clinical Oncology and Cancer Nursing (ECCO), Paris, France, Oct-Nov, 1995.
8. Nabholtz JM, Speilman M, Fumoleau P, et al. Metastatic breast cancer: a multicentre randomized trial of two doses of Taxol: interim analysis [abstract A86]. International Association for Breast Cancer Research, Biennial Meeting, Calgary, Canada, April 1993.
9. Jones S, Winer E, Vogel C, et al. Randomized comparison of vinorelbine and melphalan in anthracycline-refractory advanced breast cancer. J Clin Oncol 1995; 13: 2567-2574.
10. Lavelle F, Bissery MC, Combeau C, et al. Preclinical evaluation of docetaxel (Taxotere). Semin Oncol 1995; 22 (suppl 4): 3-16.
11. Bissery MC, Guénard D, Guéritte-Voegelein F, et al. Experimental antitumor activity of Taxotere (RP 56976, NSC 628503), a Taxol analogue. Cancer Res 1991; 51: 4845-4852.
12. Wilson WH, Berg SI, Bryant G, et al. Paclitaxel in doxorubicin-refractory or mitoxantrone-refractory breast cancer: a phase I/II trial of 96-hour infusion. J Clin Oncol 1994; 12: 1621-1629.